ROTTERDAM, The Netherlands, July 6, 2011 /PRNewswire/ --
Skyline Diagnostics B.V. (Skyline), a biotechnology company
focusing on development and marketing of gene signature-based
diagnostic assays based in The Netherlands, today announced that it
has signed a Research Agreement with Johnson & Johnson
Pharmaceutical Research and Development division of Janssen
Pharmaceutica N.V. (Janssen). Under the agreement Skyline,
using its proprietary knowledge and technologies in the area of
genetic profiling and bioinformatics will work with Janssen to
generate and analyze diagnostic information related to the use of
an undisclosed, marketed compound. Under the terms of the
agreement, Skyline will receive R&D funding and could receive
payments on the achievement of certain research milestones.
Financial details of the agreement were not disclosed.
"We are very pleased with extension
of this exciting companion diagnostic program," said Henk Viëtor,
CEO of Skyline Diagnostics, "this collaboration will provide both
companies the opportunity to develop a unique personalized medicine
approach to help identify patients at increased risk of side
AboutSkyline Diagnostics BV
Skyline Diagnostic with its headquarters in Rotterdam, The
Netherlands, develops and markets array-based diagnostic tests
using gene signatures for personalized medicine. The company has
successfully translated several important scientific discoveries
into diagnostics. These products, called Profilers, are based on
gene expression and offer a high additional clinical value. Skyline
Diagnostics' Profilers will provide the clinician in-depth insight
in the prognosis of individual patients and facilitate the
treatment decision making process. The company has built strong
collaborations with leading scientists and has strategic alliances
with industrial partners for distribution and manufacturing,
including a 'Powered by Affymetrix' partnership.
SOURCE Skyline Diagnostics B.V.